PAI
CLDX icon

Palo Alto Investors’s Celldex Therapeutics CLDX Stock Holding History

Palo Alto Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.4M Buy
+296,408
New +$8.08M 1.44% 19

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Palo Alto Investors's CLDX Position: Q1 2026 in Review

Palo Alto Investors opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 296,408 shares worth $9.4M. The stake represents 1.44% of the portfolio and ranks #19 among its holdings.

228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Palo Alto Investors held 296,408 shares of Celldex Therapeutics worth $9.4M as of Q1 2026.
  • Celldex Therapeutics was a new Palo Alto Investors position in Q1 2026.
  • Celldex Therapeutics made up 1.44% of Palo Alto Investors's portfolio in Q1 2026, its #19 holding.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.